Jim Simons Vincerx Pharma, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 121,400 shares of VINC stock, worth $98,334. This represents 0.0% of its overall portfolio holdings.

Number of Shares

121,400

Previous 176,020 31.03%

Holding current value

$98,334

Previous $208,000 195.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.07 - $8.06 $58,443 - $440,237	-54,620 Reduced 31.03%	121,400 $614,000
Q4 2023 Feb 13, 2024	BUY	$0.62 - $1.18 $26,734 - $50,881	43,120 Added 32.45%	176,020 $208,000
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.38 $17,292 - $36,156	-26,200 Reduced 16.47%	132,900 $134,000
Q2 2023 Aug 11, 2023	SELL	$0.88 - $1.9 $31,592 - $68,210	-35,900 Reduced 18.41%	159,100 $207,000
Q1 2023 May 12, 2023	BUY	$0.9 - $1.51 $12,600 - $21,140	14,000 Added 7.73%	195,000 $203,000

Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.08 $81,728 - $137,916	-127,700 Reduced 41.37%	181,000 $185,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $1.72 $0 - $6,573	-3,822 Reduced 1.22%	308,700 $426,000
Q2 2022 Aug 12, 2022	BUY	$0.0 - $0.0 $0 - $0	170,778 Added 120.48%	312,522 $413,000
Q1 2022 May 13, 2022	BUY	$0.0 - $0.0 $0 - $0	141,744 New	141,744 $567,000
Q4 2021 Feb 11, 2022	SELL	$0.0 - $0.0 $0 - $0	-30,600 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$0.0 - $0.0 $0 - $0	-38,500 Reduced 55.72%	30,600 $495,000
Q2 2021 Aug 13, 2021	BUY	$0.0 - $27.0 $0 - $1.87 Million	69,100 New	69,100 $898,000

Others Institutions Holding VINC

# of Institutions

Shares Held

8.46M

Call Options Held

Put Options Held

View Full List

About Vincerx Pharma, Inc.

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $17.2M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

More about VINC

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account